Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NXT 211

Drug Profile

NXT 211

Alternative Names: Anti-ferritin antibody-Y90; NXT211; Radiolabelled anti-isoferritin antibody

Latest Information Update: 29 Jun 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEXTherapeutics
  • Class Antibodies; Antibody diagnostics; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Hodgkin's disease

Most Recent Events

  • 29 Jun 2011 No development reported - Clinical-Phase-Unknown for Hodgkin's disease in USA (unspecified route)
  • 29 Jun 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 17 Feb 2004 Preclinical trials in Cancer (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top